Recently published results of II and II phase clinical trials of alemtuzumab in relapsing-remitting multiple sclerosis (MS) are reviewed. This drug has an immunosuppressive mechanism of action with an anti-inflammatory effect higher than that of high-dose beta-interferon. Its neuroprotective activity and possible side-effects are discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
multiple sclerosis
8
[alemtuzumab drug
4
drug based
4
based monoclonal
4
monoclonal antibodies
4
antibodies treatment
4
treatment multiple
4
sclerosis treatment
4
treatment possibilities
4
possibilities risksreview]
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!